{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:24:42Z","timestamp":1793953482421,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.psyneuen.2026.107838","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:05:41Z","timestamp":1773680741000},"page":"107838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond dose: Antipsychotic risk categories and sex-specific vulnerability to hyperprolactinemia in real-world longitudinal care"],"prefix":"10.1016","volume":"188","author":[{"given":"Zeynep","family":"\u00d6zt\u00fcrk Yal\u00e7\u0131n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2694-4072","authenticated-orcid":false,"given":"\u0130zgi","family":"Bayraktar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Ka\u015f\u0131kc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadir","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u00e7in","family":"\u00d6z\u00e7elik Ero\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Elif An\u0131l","family":"Ya\u011fc\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeref Can","family":"G\u00fcrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psyneuen.2026.107838_bib1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/13651501.2018.1425459","article-title":"Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications","volume":"22","author":"Alosaimi","year":"2018","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.psyneuen.2026.107838_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41386-018-0125-6","article-title":"Sex differences in neural mechanisms mediating reward and addiction","volume":"44","author":"Becker","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psyneuen.2026.107838_bib3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.psyneuen.2026.107838_bib4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/YCO.0000000000000699","article-title":"Estrogens in schizophrenia: progress, current challenges and opportunities","volume":"34","author":"Brand","year":"2021","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2026.107838_bib5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","article-title":"Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics","volume":"21","author":"Bushe","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2026.107838_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2023.106392","article-title":"Blood concentrations of anterior pituitary hormones in drug-naive people with first-episode psychosis: a systematic review and meta-analysis","volume":"158","author":"Cavaleri","year":"2023","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2026.107838_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"58","author":"Chen","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2026.107838_bib8","article-title":"Current perspectives on chlorpromazine equivalents: comparing apples and oranges!","volume":"55","author":"Danivas","year":"2013","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2026.107838_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228648","article-title":"Prolactin response to antipsychotics: An inpatient study","volume":"15","author":"Dehelean","year":"2020","journal-title":"PLOS One"},{"key":"10.1016\/j.psyneuen.2026.107838_bib10","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/npp.2010.111","article-title":"Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial","volume":"35","author":"Gaebel","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psyneuen.2026.107838_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psyneuen.2026.107838_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/pr.109.002071","article-title":"Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines","volume":"62","author":"Gillies","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.psyneuen.2026.107838_bib13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/j.2040-4603.2016.tb00694.x","article-title":"Regulation of the hypothalamic-pituitary-adrenocortical stress response","volume":"6","author":"Herman","year":"2016","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.psyneuen.2026.107838_bib14","article-title":"Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review","volume":"133","author":"Hert","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psyneuen.2026.107838_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/jne.70098","article-title":"Dopamine and prolactin in migraine: mechanisms and potential therapeutic targets","volume":"37","author":"Hjelholt","year":"2025","journal-title":"J. Neuroendocr."},{"key":"10.1016\/j.psyneuen.2026.107838_bib16","first-page":"1","article-title":"The R package geepack for generalized estimating equations","volume":"15","author":"H\u00f8jsgaard","year":"2005","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.psyneuen.2026.107838_bib17","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.psyneuen.2026.107838_bib18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2174\/1570159X21666221027143920","article-title":"Sex differences in serum prolactin levels in children and adolescents on antipsychotics: a systematic review and meta-analysis","volume":"21","author":"Ilzarbe","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.psyneuen.2026.107838_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1337274","article-title":"Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses","volume":"15","author":"Jiang","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psyneuen.2026.107838_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41537-023-00430-4","article-title":"Sex differences in autonomic adverse effects related to antipsychotic treatment and associated hormone profiles","volume":"10","author":"Johansen","year":"2024","journal-title":"Schizophrenia"},{"key":"10.1016\/j.psyneuen.2026.107838_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40290-023-00462-2","article-title":"Clinical presentations of drug-induced hyperprolactinaemia: a literature review","volume":"37","author":"Junqueira","year":"2023","journal-title":"Pharm. Med."},{"key":"10.1016\/j.psyneuen.2026.107838_bib22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.9758\/cpn.23.1057","article-title":"Prolactin level changes according to atypical antipsychotics use: a study based on clinical data warehouse","volume":"21","author":"Kim","year":"2023","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"1","key":"10.1016\/j.psyneuen.2026.107838_bib23","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psyneuen.2026.107838_bib24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s40263-025-01218-z","article-title":"Antipsychotic-related prolactin changes: a systematic review and dose\u2013response meta-analysis","volume":"39","author":"Lin","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psyneuen.2026.107838_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-022-02027-4","article-title":"Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis","volume":"12","author":"Lu","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.psyneuen.2026.107838_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2125.2001.01352.x","article-title":"Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses","volume":"51","author":"Melkersson","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.psyneuen.2026.107838_bib27","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","article-title":"Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"Montgomery","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2026.107838_bib28","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psyneuen.2026.107838_bib29","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psyneuen.2026.107838_bib30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jaac.2023.05.003","article-title":"Editorial: a better perspective on antipsychotic-related hyperprolactinemia in children and adolescents","volume":"62","author":"Strawn","year":"2023","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.psyneuen.2026.107838_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2012.12.027","article-title":"Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics","volume":"145","author":"Suzuki","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2026.107838_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00716-z","article-title":"Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors","volume":"8","author":"Sykes","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.psyneuen.2026.107838_bib33","series-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2021"},{"key":"10.1016\/j.psyneuen.2026.107838_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.9740\/mhc.2016.07.185","article-title":"Management of antipsychotic-induced hyperprolactinemia","volume":"6","author":"Tewksbury","year":"2016","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.psyneuen.2026.107838_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fendo.2016.00025","article-title":"Actions of prolactin in the brain: from physiological adaptations to stress and neurogenesis to psychopathology","volume":"7","author":"Torner","year":"2016","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.psyneuen.2026.107838_bib36","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","article-title":"Aripiprazole, A drug that displays partial agonism and functional selectivity","volume":"15","author":"Tuplin","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.psyneuen.2026.107838_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/sj.npp.1301071","article-title":"Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways","volume":"32","author":"Urban","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psyneuen.2026.107838_bib38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1192\/bjp.182.3.199","article-title":"Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences","volume":"182","author":"Wieck","year":"2003","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2026.107838_bib39","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1080\/02664763.2012.700452","article-title":"A new look at the difference between the GEE and the GLMM when modeling longitudinal count responses","volume":"39","author":"Zhang","year":"2012","journal-title":"J. Appl. Stat."},{"key":"10.1016\/j.psyneuen.2026.107838_bib40","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s40263-025-01216-1","article-title":"Patterns of serum prolactin elevation associated with nine second-generation antipsychotics in a large cohort of patients with schizophrenia","volume":"39","author":"Zhang","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psyneuen.2026.107838_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00213-004-1975-7","article-title":"Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study","volume":"178","author":"Zhang","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psyneuen.2026.107838_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2019-100091","article-title":"Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis","volume":"32","author":"Zheng","year":"2019","journal-title":"Gen. Psychiatr."},{"key":"10.1016\/j.psyneuen.2026.107838_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","article-title":"Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis","volume":"237","author":"Zhu","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2026.107838_bib44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40258-024-00937-6","article-title":"Cost-effective and sustainable drug use in hospitals: a systematic and practice-based approach","volume":"23","author":"Zietse","year":"2025","journal-title":"Appl. Health Econ. Health Policy"}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453026000983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453026000983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:31:18Z","timestamp":1793950278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453026000983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"alternative-id":["S0306453026000983"],"URL":"https:\/\/doi.org\/10.1016\/j.psyneuen.2026.107838","relation":{},"ISSN":["0306-4530"],"issn-type":[{"value":"0306-4530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond dose: Antipsychotic risk categories and sex-specific vulnerability to hyperprolactinemia in real-world longitudinal care","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psyneuen.2026.107838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107838"}}